Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBH4FL)

Drug Name
BI 655066 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic plaque psoriasis EA90.0 Phase 3 [1]
Ankylosing spondylitis FA92.0 Phase 2 [2]
Crohn disease DD70 Phase 2 [1]
Psoriatic arthritis FA21 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMBH4FL

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Chronic plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02443298) Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.. U.S. National Institutes of Health.
3 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.